nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3208Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESПрименение низкомолекулярного гепарина-фрагмина при нефротическом синдроме у детейLow molecular weight heparin-fragmin in treatment of children with nephrotic syndromeВознесенскаяТ. С.VoznesenskyaT. S.noemail@neicon.ruЗябкинаА. Г.ZiabkinaA. G.noemail@neicon.ruСергееваТ. В.SergeevaT. V.noemail@neicon.ruНИИ педиатрии НЦЗД РАМНRussian Federation200228062025413840Copyright © Вознесенская Т.С., Зябкина А.Г., Сергеева Т.В., 20252025Вознесенская Т.С., Зябкина А.Г., Сергеева Т.В.Voznesenskya T.S., Ziabkina A.G., Sergeeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3208

В связи с отсутствием единой схемы лечения и профилактики тромботических осложнений при нефротическом синдроме проведено исследование эффективности и безопасности применения низкомолекулярного гепарина-фрагмина у детей с нефротическим синдромом. Фрагмин применялся с профилактической целью в дозе от 2500 МЕ/сут до 5000 МЕ/сут 1 раз в день подкожно под контролем уровня фактора свертывания антиХа в течение 3 недель. За время лечения не было зарегистрировано кровотечений, тромбоцитопении. Уровень фибриногена снизился у всех больных. Протромбиновый комплекс оставался в пределах нормы даже при наслоении ОРЗ с нарастанием активности заболевания. В результате исследования была показана эффективность и безопасность фрагмина в вышеуказанных дозах для лечения детей с нефротическим синдромом.

There is no consensus on the optimal therapeutic and prophylactic approach for thrombotic complications in nephrotic syndrome, so the investigation was performed to evaluate the efficacy and safety of low molecular weight heparin-fragmin in nephrotic children. Fragmin was given in prophylactic dose (2500-5000 ME/24 h once a day) for 3 weeks with measurement of anti Хa activity. There was no evidence of bleeding and/or thrombocytopenia at the time of treatment. In all patients fibrinogen level decreased after fragmin treatment. Prothrombin complex was in normal limits even if respiratory infection was developed with increasing of disease activity. This study demonstrates the efficacy and safety of fragmin in therapy of nephrotic syndrom in children in above-mentioned dose.

нефротический синдромтромботические осложненияфрагминReferencesAbella E.M. Hemostatic problems associated with renal disease. Int J Pediatr Hematol Oncol 1994; 1: 43-51.Abella E.M. Hemostatic problems associated with renal disease. Int J Pediatr Hematol Oncol 1994; 1: 43-51.Alkjaersig N., Fletcher A.P., Narayanan M. et al. Course and resolution of the coagulopathy in nephrotic children. Kidney Int 1987; 31: 772-780.Alkjaersig N., Fletcher A.P., Narayanan M. et al. Course and resolution of the coagulopathy in nephrotic children. Kidney Int 1987; 31: 772-780.Hoyer P.F., Gonda S., Barthels M. et al. Thromboembolic complications in children with nephrotic syndrome, risk and incidence. Acta Paediatr Scand 1986; 75: 804-810.Hoyer P.F., Gonda S., Barthels M. et al. Thromboembolic complications in children with nephrotic syndrome, risk and incidence. Acta Paediatr Scand 1986; 75: 804-810.Llach F., Papper S., Massry S.G. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of the nephrotic syndrome. Kidney Int 1985; 28: 429-439.Llach F., Papper S., Massry S.G. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of the nephrotic syndrome. Kidney Int 1985; 28: 429-439.Andrassay K., Ritz E., Brommer J. Hypercoagulability in the nephrotic syndrome. Klin Wochenschr 1980; 58: 1029-1036.Andrassay K., Ritz E., Brommer J. Hypercoagulability in the nephrotic syndrome. Klin Wochenschr 1980; 58: 1029-1036.Kauffmann R.H., Veltkamp J.J., Tilburg N.H. et al. Acquired antithrombin-3 deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-613.Kauffmann R.H., Veltkamp J.J., Tilburg N.H. et al. Acquired antithrombin-3 deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-613.Lilova M.I., Velkovski I.G., Topalov I.B. Thromboembolic complications in children with nephrotic syndrome in Bulgaria. Pediatr Nephrol 2000; 15: 74-78.Lilova M.I., Velkovski I.G., Topalov I.B. Thromboembolic complications in children with nephrotic syndrome in Bulgaria. Pediatr Nephrol 2000; 15: 74-78.Cameron J.S. Thromboembolic complications of the nephrotic syndrome. Adv Nephrol 1984; 13: 75-114.Cameron J.S. Thromboembolic complications of the nephrotic syndrome. Adv Nephrol 1984; 13: 75-114.Mehls O., Andrassy K., Koderisch J. et al. Hemostasis and thromboembolism in children with nephrotic syndrome: differences from adults. J Pediatr 1987; 110: 862-867.Mehls O., Andrassy K., Koderisch J. et al. Hemostasis and thromboembolism in children with nephrotic syndrome: differences from adults. J Pediatr 1987; 110: 862-867.Sagripanti A., Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron 1995; 70: 271-281.Sagripanti A., Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron 1995; 70: 271-281.Fahal I.H., McClelland P., Hay C.R. et al. Arterial thrombosis in the nephrotic syndrome. Postgrad Med J 1994; 70: 905-909.Fahal I.H., McClelland P., Hay C.R. et al. Arterial thrombosis in the nephrotic syndrome. Postgrad Med J 1994; 70: 905-909.Cameron J.S. The nephrotic syndrome: management, complications and pathophysiology. In: Davison A.M., Cameron J.S., Grunfeld J.-P. et al. (eds) Oxford textbook of clinical nephrology. Oxford University Press; London, 1997; 461-492.Cameron J.S. The nephrotic syndrome: management, complications and pathophysiology. In: Davison A.M., Cameron J.S., Grunfeld J.-P. et al. (eds) Oxford textbook of clinical nephrology. Oxford University Press; London, 1997; 461-492.Monno R., Grandaliano G., Faccio R. et al. Activated coagulation factor Хa: novel mitogenic stimulus for mesangial cells. J Am Soc Nephrol 2001; 12: 891-899.Monno R., Grandaliano G., Faccio R. et al. Activated coagulation factor Хa: novel mitogenic stimulus for mesangial cells. J Am Soc Nephrol 2001; 12: 891-899.

The authors declare that there are no conflicts of interest present.